RLMD
Relmada Therapeutics·NASDAQ
--
--(--)
--
--(--)
3.80 / 10
Netural
Analyst coverage is limited but positive: Leerink Partners recently upgraded RLMD to 'Outperform' with a $8.00 target. Fund-flow data show a 7.6/10 score with net inflows in Small and Medium patterns, despite a negative overall trend, indicating constructive institutional interest. Together, the analyst upgrade and positive fund-flow signals reinforce a bullish sentiment, though the low analyst count warrants caution.
Fund Flow Rating
Analyst RatingBuy
Wall Street Opinions
Buy
Strong Buy
0%
Buy
100%
Hold
0%
Sell
0%
Strong Sell
0%
Date2026-01-23
InstitutionLeerink Partners
Times predicted1
Historical Win Rate0.0%
What is the market sentiment for RLMD?
- RLMD holds a Bearish analyst rating, with 100% of experts assigning a Buy grade. Factoring in net Outflows from order flow data, the comprehensive Sentiment Score stands at 3.80/10 (Netural).
